blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP0675961

EP0675961 - Treatment of tumorigenic disease with a modified HSV [Right-click to bookmark this link]
Former [1995/41]METHODS AND COMPOSITIONS FOR GENE, TUMOR, AND VIRAL INFECTION THERAPY, AND PREVENTION OF PROGRAMMED CELL DEATH (APOPTOSIS)
[2002/03]
StatusPatent revoked
Status updated on  10.08.2012
Database last updated on 26.06.2024
Most recent event   Tooltip19.04.2013Lapse of the patent in a contracting state
New state(s): AT, BE, DK, ES, IT, NL, SE		published on 22.05.2013  [2013/21]
Applicant(s)For all designated states
Arch Development Corporation
1101 East 58th Street, The University of Chicago Chicago
Illinois 60637 / US
[N/P]
Former [1995/41]For all designated states
ARCH DEVELOPMENT CORPORATION
1101 East 58th Street, The University of Chicago
Chicago, Illinois 60637 / US
Inventor(s)01 / ROIZMAN, Bernard
5555 S. Everett
Chicago, IL 60637 / US
02 / CHOU, Joany
5227 S. Kimbark
Chicago, IL 60615 / US
[1995/41]
Representative(s)Bösl, Raphael Konrad, et al
Patentanwälte Isenbruck Bösl Hörschler PartG mbB
Eastsite One
Seckenheimer Landstraße 4
68163 Mannheim / DE
[N/P]
Former [2008/38]Bösl, Raphael Konrad, et al
Patentanwälte Isenbruck Bösl Hörschler Wichmann Huhn Prinzregentenstrasse 68
81675 München / DE
Former [2004/10]Bösl, Raphael, Dr. rer. nat., Dipl.-Chem., et al
Patentanwälte Isenbruck Bösl Hörschler Wichmann Huhn Postfach 860 880
81635 München / DE
Former [1995/41]Ritter, Stephen David, et al
Mathys & Squire 100 Grays Inn Road
London WC1X 8AL / GB
Application number, filing date93907093.426.02.1993
[1995/41]
WO1993US01801
Priority number, dateUS1992086123331.03.1992         Original published format: US 861233
[1995/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO9319591
Date:14.10.1993
Language:EN
[1993/25]
Type: A1 Application with search report 
No.:EP0675961
Date:11.10.1995
Language:EN
The application published by WIPO in one of the EPO official languages on 14.10.1993 takes the place of the publication of the European patent application.
[1995/41]
Type: B1 Patent specification 
No.:EP0675961
Date:27.11.2002
Language:EN
[2002/48]
Search report(s)International search report - published on:US14.10.1993
(Supplementary) European search report - dispatched on:EP10.01.1996
ClassificationIPC:C12N15/869, C12N15/38, A61K39/245
[2011/42]
CPC:
G01N33/5011 (EP,US); A61K38/162 (EP,US); A61K39/12 (EP,US);
A61K39/245 (EP,US); A61P25/00 (EP); A61P31/12 (EP);
A61P31/22 (EP); A61P35/00 (EP); A61P43/00 (EP);
C07K14/005 (EP,US); C12N15/86 (EP,US); G01N33/5008 (EP,US);
G01N33/502 (EP,US); G01N33/5058 (EP,US); G01N33/5073 (EP,US);
A61K48/00 (EP,US); C12N2710/16622 (EP,US); C12N2710/16634 (EP,US);
C12N2710/16643 (EP,US); G01N2510/00 (EP,US) (-)
Former IPC [2005/33]C12N15/86, C12N15/38, C07K13/00, A61K37/02, A61K39/245, G01N33/50, A61K48/00
Former IPC [2002/03]C12N15/869, C12N15/38, C07K14/035, A61K39/245, G01N33/50, A61K48/00
Former IPC [1995/41]C12N15/86, C12N15/38, C07K13/00, A61K37/02, A61K39/245, G01N33/50, A61K48/00
Designated contracting statesAT,   BE,   CH,   DE,   DK,   ES,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [1995/41]
TitleGerman:Behandlung von Tumorerkrankungen mit modifiziertem HSV[2002/03]
English:Treatment of tumorigenic disease with a modified HSV[2002/03]
French:Traitement de maladies tumorigéniques à l'aide d'un HSV modifié[2002/03]
Former [1995/41]METHODEN UND ZUSAMMENSETZUNGEN FÜR DIE GEN-, TUMOR- UND VIRALE INFEKTIONSTHERAPY UND VERHINDERUNG DES PROGRAMMIERTEN ZELLTOD
Former [1995/41]METHODS AND COMPOSITIONS FOR GENE, TUMOR, AND VIRAL INFECTION THERAPY, AND PREVENTION OF PROGRAMMED CELL DEATH (APOPTOSIS)
Former [1995/41]PROCEDES ET COMPOSITIONS UTILISES EN THERAPIE GENIQUE ET POUR LA THERAPIE CONTRE LES TUMEURS ET LES INFECTIONS VIRALES, ET POUR LA PREVENTION DE LA MORT CELLULAIRE PROGRAMMEE (APOPTOSE)
Entry into regional phase07.10.1994National basic fee paid 
07.10.1994Search fee paid 
07.10.1994Designation fee(s) paid 
07.10.1994Examination fee paid 
Examination procedure28.10.1993Request for preliminary examination filed
International Preliminary Examining Authority: DE
07.10.1994Examination requested  [1995/41]
29.01.2001Despatch of a communication from the examining division (Time limit: M06)
30.07.2001Reply to a communication from the examining division
20.08.2001Despatch of a communication from the examining division (Time limit: M04)
20.11.2001Reply to a communication from the examining division
08.02.2002Despatch of communication of intention to grant (Approval: Yes)
18.06.2002Communication of intention to grant the patent
09.08.2002Fee for grant paid
09.08.2002Fee for publishing/printing paid
04.04.2006Observations by third parties
Opposition(s)Opponent(s)01  25.08.2003  30.09.2003  ADMISSIBLE
BIOVEX LIMITED
70 Milton Park
Abingdon Oxford OX14 4RX / GB
Opponent's representative
Woods, Geoffrey Corlett
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
 [N/P]
Former [2008/29]
Opponent(s)01  25.08.2003  30.09.2003  ADMISSIBLE
BIOVEX LIMITED
70 Milton Park
Abingdon Oxford OX14 4RX / GB
Opponent's representative
Woods, Geoffrey Corlett
J.A. KEMP & CO. 14 South Square Gray's Inn London
WC1R 5JJ / GB
Former [2003/43]
Opponent(s)01  25.08.2003   
BioVex Limited
70 Milton Park
Abingdon Oxford OX14 4RX / GB
Opponent's representative
Woods, Geoffrey Corlett
J.A. KEMP & CO., Gray's Inn, 14 South Square
London WC1R 5JJ / GB
06.10.2003Invitation to proprietor to file observations on the notice of opposition
16.04.2004Reply of patent proprietor to notice(s) of opposition
17.02.2005Date of oral proceedings
21.03.2005Despatch of interlocutory decision in opposition
21.03.2005Despatch of minutes of oral proceedings
04.04.2007Despatch of a communication from the opposition division (Time limit: M02)
14.06.2007Reply to a communication from the opposition division
24.09.2007Despatch of a communication from the opposition division (Time limit: M02)
19.11.2007Reply to a communication from the opposition division
10.01.2008Despatch of a communication from the opposition division (Time limit: M02)
19.03.2008Reply to a communication from the opposition division
09.10.2008Cancellation of oral proceeding that was planned for 29.10.2008
09.10.2008Despatch of minutes of oral proceedings
29.10.2008Date of oral proceedings
27.07.2011Legal effect of interlocutory decision in opposition
16.09.2011Despatch of communication that the patent will be maintained as amended
27.04.2012Despatch of communication that the patent will be revoked
07.05.2012Legal effect of revocation of patent [2012/37]
Appeal following opposition15.01.2009Appeal received No.  T0310/09
09.03.2009Statement of grounds filed
27.07.2011Result of appeal procedure: appeal of the proprietor withdrawn
18.05.2005Appeal received No.  T0665/05
01.08.2005Statement of grounds filed
10.10.2006Result of appeal procedure: maintenance in amended form
27.05.2005Appeal received No.  T0665/05
28.07.2005Statement of grounds filed
10.10.2006Result of appeal procedure: maintenance in amended form
10.10.2006Date of oral proceedings
13.10.2006Minutes of the oral proceedings despatched
Fees paidRenewal fee
10.02.1995Renewal fee patent year 03
08.02.1996Renewal fee patent year 04
26.02.1997Renewal fee patent year 05
11.02.1998Renewal fee patent year 06
10.02.1999Renewal fee patent year 07
11.02.2000Renewal fee patent year 08
15.02.2001Renewal fee patent year 09
13.02.2002Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCH27.11.2002
GR27.11.2002
LI27.11.2002
IE26.02.2003
LU26.02.2003
PT27.02.2003
MC28.02.2003
AT26.02.2011
IT26.02.2011
ES27.02.2011
SE27.02.2011
BE28.02.2011
DK28.02.2011
NL01.09.2011
[2013/21]
Former [2005/02]CH27.11.2002
GR27.11.2002
LI27.11.2002
IE26.02.2003
LU26.02.2003
PT27.02.2003
MC28.02.2003
Former [2004/39]CH27.11.2002
GR27.11.2002
LI27.11.2002
IE26.02.2003
LU26.02.2003
PT27.02.2003
Former [2004/15]CH27.11.2002
GR27.11.2002
LI27.11.2002
IE26.02.2003
PT27.02.2003
Former [2003/39]CH27.11.2002
GR27.11.2002
LI27.11.2002
PT27.02.2003
Former [2003/31]GR27.11.2002
PT27.02.2003
Former [2003/29]PT27.02.2003
Documents cited:Search[A]EP0243155  (MERIEUX INST [FR]) [A] 1-4,7-9 * page 4, line 7 - line 23 * * page 7, line 3 - line 12 * * page 13, line 23 - line 32 * * page 14, line 1 - line 11 * * page 23 *;
 [A]EP0453242  (GEN HOSPITAL CORP [US]) [A] 1-4,7-9 * the whole document *;
 [A]WO9204050  (ROIZMAN BERNARD [US]) [A] 1-9,14-21,23-25,31-33 * the whole document *;
 [X]  - CHOU ET AL., "Mapping of Herpes Simplex virus-1 Neurovirulence to gamma134.5, a gene nonessential for growth in culture", SCIENCE, (1990), vol. 250, no. 4985, pages 1262 - 1266, XP000255907 [X] 1,2,7,9,14-21 * the whole document *

DOI:   http://dx.doi.org/10.1126/science.2173860
 [AD]  - CHOU ET AL., "The Herpes Simplex Virus 1 gene for ICP34.5, which maps in inverted repeats, is conserved in several limited-passage isolates but not in strain 17syn+", J. VIROLOGY, (199003), vol. 64, no. 3, pages 1014 - 1020, XP008049066 [AD] 1-9,14-21 * page 1018 *
International search[Y]  - HENDERSON S,ET AL, "Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death.", CELL, CELL PRESS, US, US, (19910628), vol. 65, no. 7, doi:10.1016/0092-8674(91)90007-L, ISSN 0092-8674, pages 1107 - 1115, XP002224486

DOI:   http://dx.doi.org/10.1016/0092-8674(91)90007-L
 [Y]  - STRASSER A., HARRIS A. W., CORY S., "BCL- TRANSGENE INHIBITS T CELL DEATH AND PERTURBS THYMIC SELF-CENSORSHIP.", CELL, CELL PRESS, US, US, (19911129), vol. 67., no. 06., doi:10.1016/0092-8674(91)90362-3, ISSN 0092-8674, pages 889 - 899., XP002014059

DOI:   http://dx.doi.org/10.1016/0092-8674(91)90362-3
 [Y]  - SENTMAN C.L. ET AL, "bcl-2 Inhibits Multiple Forms of Apoptosis but Not Negative Selection in Thymocytes", CELL, CELL PRESS, US, US, (19911129), vol. 67, doi:10.1016/0092-8674(91)90361-2, ISSN 0092-8674, pages 879 - 888, XP002987880

DOI:   http://dx.doi.org/10.1016/0092-8674(91)90361-2
 [Y]  - GREGORY C. D., ET AL., "ACTIVATION OF EPSTEIN-BARR VIRUS LATENT GENES PROTECTS HUMAN B CELLS FROM DEATH BY APOPTOSIS.", NATURE, Nature Publishing Group, United Kingdom, United Kingdom, (19910214), vol. 349., doi:10.1038/349612a0, ISSN 0028-0836, pages 612 - 614., XP002038738

DOI:   http://dx.doi.org/10.1038/349612a0
by applicantUS4769331
    - HENDERSON ET AL., CELL, vol. 65, pages 1107 - 1991
    - LORD ET AL., NUCLEIC ACID RES., (1990), vol. 18, page 2823
    - DELUCA ET AL., J. VIROL., (1985), vol. 56, pages 558 - 570
    - POST; ROIZMAN, CELL, (1991), vol. 25, page 227
    - SNYDER ET AL., CELL, (1992), vol. 68, pages 33 - 51
    - RANFRANZ ET AL., CELL, (1991), vol. 66, pages 713 - 729
    - RYDER ET AL., J. NEUROBIOL., (1990), vol. 21, pages 356 - 375
    - ACKERMAN ET AL., J. VIROL., (1986), vol. 58, pages 843 - 850
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.